Wealthcare Advisory Partners LLC Boosts Holdings in Eli Lilly and Company (NYSE:LLY)

Wealthcare Advisory Partners LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 11.4% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 6,434 shares of the company’s stock after buying an additional 659 shares during the quarter. Wealthcare Advisory Partners LLC’s holdings in Eli Lilly and Company were worth $3,750,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in LLY. JB Capital LLC boosted its position in Eli Lilly and Company by 12.8% during the third quarter. JB Capital LLC now owns 935 shares of the company’s stock worth $502,000 after purchasing an additional 106 shares during the period. WealthShield Partners LLC boosted its position in Eli Lilly and Company by 134.6% during the third quarter. WealthShield Partners LLC now owns 2,067 shares of the company’s stock worth $1,110,000 after purchasing an additional 1,186 shares during the period. Verdence Capital Advisors LLC boosted its position in Eli Lilly and Company by 27.1% during the third quarter. Verdence Capital Advisors LLC now owns 7,266 shares of the company’s stock worth $3,903,000 after purchasing an additional 1,551 shares during the period. BluePath Capital Management LLC bought a new position in Eli Lilly and Company during the third quarter worth about $384,000. Finally, Mackenzie Financial Corp boosted its position in Eli Lilly and Company by 5.0% during the third quarter. Mackenzie Financial Corp now owns 339,719 shares of the company’s stock worth $178,417,000 after purchasing an additional 16,045 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Bank of America increased their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Wells Fargo & Company raised their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a research report on Wednesday, February 21st. Barclays raised their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. Finally, TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $757.95.

Eli Lilly and Company Stock Performance

NYSE:LLY traded up $31.77 during mid-day trading on Monday, reaching $766.74. The company’s stock had a trading volume of 3,396,224 shares, compared to its average volume of 3,090,840. Eli Lilly and Company has a 12-month low of $419.80 and a 12-month high of $800.78. The firm’s fifty day moving average price is $760.96 and its two-hundred day moving average price is $673.52. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The stock has a market cap of $728.72 billion, a P/E ratio of 112.92, a PEG ratio of 1.45 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. During the same quarter in the prior year, the firm earned $1.62 EPS. The business’s revenue for the quarter was up 26.0% compared to the same quarter last year. On average, equities analysts forecast that Eli Lilly and Company will post 13.82 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.68%. Eli Lilly and Company’s payout ratio is currently 76.58%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.